Application of edaravondex borneol-containing composition in the treatment of cognitive impairment
A synergistic pharmaceutical composition of edaravone and borneol effectively treats cognitive disorders by enhancing cognitive function and reducing Alzheimer's disease pathology, surpassing individual therapies in efficacy.
Patent Information
- Application Number
- JP2024527204
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-08
- Filing Date
- 2022-11-03
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for cognitive disorders, particularly Alzheimer's disease, are ineffective in curing or significantly slowing disease progression, and there is a need for more effective therapies.
A pharmaceutical composition combining 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone) and borneol, preferably dexborneol, is administered to treat cognitive dysfunctions, with a weight ratio of 10:1 to 1:8, synergistically enhancing therapeutic efficacy.
The composition improves cognitive function, restores long-term potentiation in the hippocampal region, ameliorates Alzheimer's disease pathology, and reduces amyloid plaques, astrocyte proliferation, and tau protein hyperphosphorylation, offering superior effects compared to individual therapies.
Smart Images

Figure 2024543056000007 
Figure 2024543056000008 
Figure 2024543056000009
Abstract
Description
[Technical field]
[0001] This application claims priority to a Chinese patent application filed with the China Patent Office on November 8, 2021, bearing application number 202111311631.1 and titled "Application of edaravondex borneol-containing composition in treating cognitive disorder," the entire contents of which are incorporated herein by reference.
[0002] The present invention belongs to the pharmaceutical field and relates to the application of a composition of 3-methyl-1-phenyl-2-pyrazolin-5-one or a pharma-ceutically acceptable salt thereof and borneol in the treatment of cognitive impairment. [Background technology]
[0003] Dementia is a syndrome that is centered on acquired cognitive impairment and causes obvious decline in patients' daily living, learning, work and social communication abilities. Patients' cognitive impairments involve memory, learning, orientation, comprehension, judgment, calculation, language, visuospatial function, analysis and problem-solving abilities, and are often accompanied by mental, behavioral and personality abnormalities at some stage of the disease course. Dementia includes degenerative and non-degenerative dementias, the former including Alzheimer's disease (AD), dementia with Lewy bodies (DLB), frontotemporal lobar degeneration (FTLD) and the latter including vascular dementia (VaD), normal pressure hydrocephalus and dementia due to other diseases such as traumatic brain injury, infection, immunity, tumor, poisoning and metabolic diseases (2018 Chinese Dementia and Cognitive Disorders Diagnostic Guideline, Chinese Medical Journal, 2018.98 (13), p: 965-970).
[0004] AD is a neurodegenerative disease that develops slowly and worsens over time, and is the only disease that cannot currently be cured, prevented, or slowed down. In 2020, AD ranked 7th among the top 10 causes of death in the world announced by the WHO. The most common early symptom of AD is short-term memory loss (difficulty remembering recent events), and as the disease progresses, symptoms can gradually appear, including speech disorders, disorientation (including being confused), mood lability, loss of motivation, inability to take care of oneself, and many behavioral problems. As the situation worsens, patients may become isolated from their families or society due to the cause, gradually losing physical function and dying. Although the course of the disease varies from person to person, the average life expectancy after diagnosis is about 3 to 9 years.
[0005] According to the World Alzheimer's Report 2021 published by the International Alzheimer's Society, as of 2019, there were a total of 55 million Alzheimer's patients in the world, but with the trend of aging, it is predicted that the number of AD patients will reach 78 million worldwide in 2030 and 129 million in 2050. China has already entered a stage of rapid population aging development, and the number of elderly population continues to increase. By the end of 2018, China's elderly population aged 60 years or older reached 249 million, accounting for 17.9% of the total population, and the elderly population aged 65 years or older reached 166 million, accounting for 11.9% of the total population. According to the 2017 National Epidemiological Survey of Mental Disorders, the prevalence of late-life dementia in China's population aged 65 years or older is 5.56% (The Lancet Psychiatry, 2019. 6(3): p. 211-224). According to a recent meta-analysis, the total prevalence of dementia in the Chinese population aged 60 years or older is 5.3%. There are approximately 10-11 million dementia patients aged 60 years or older, of which 60% have AD (The Lancet Neurology, 2020. 19(1): p. 81-92.).
[0006] Five "existing drugs" approved by the US FDA can alleviate some symptoms in AD patients, including four cholinesterase inhibitors, tacrine (withdrawn from the market due to hepatotoxicity), donepezil, galantamine, rivastigmine, and one NMDAR antagonist, memantine (Molecules, 2020. 25(24)). In addition, sodium oligomanate capsules (Jiu Qu Yi (registered trademark), GV-971, low molecular weight acidic oligosaccharides), conditionally approved by the Chinese NMPA in November 2019, target the brain-gut axis and improve cognitive function in mild to moderate AD patients (First Approval. Drugs, 2020. 80(4): p. 441-444). Aducanumab (Aduhelm®, anti-Aβmab), an IgG1 monoclonal antibody drug targeting soluble and insoluble Aβ amyloid, was conditionally approved by the US FDA on June 7, 2021 for treating patients with mild cognitive impairment or mild AD (First Approval. Drugs, 2021. 81(12): p. 1437-1443.). However, currently, all approved drugs are still unable to cure AD, and more effective AD treatments that can slow the progression of the disease are needed in clinical practice.
[0007] 3-Methyl-1-phenyl-2-pyrazolin-5-one (edaravone) is a small molecule compound that can scavenge free radicals. In vitro, edaravone inhibited Aβ in a concentration-dependent manner in the concentration range of 0.156 to 5 μM. 1-42 Edaravone can inhibit the aggregation of Aβ monomers into Aβ protofibrils and depolymerize Aβ protofibrils, and has been shown to have an anti-β1 inhibitory effect on ASH-SY5Y and primary cortical neurons. 1-42It can reduce the neurotoxicity of APP695, improve cell viability, and maintain neurite growth. In SY-SY5Y (SH-SY5Y-APP695) cells stably expressing APP695 protein, edaravone (0.3-3 μM) can concentration-dependently reduce BACE1 expression and Aβ production by APP cleavage, inhibit GSK-3β activation, and reduce tau phosphate levels (Proc Natl Acad Sci USA, 2015. 112(16): p. 5225-30). In addition, edaravone can reduce H2O2- and glutamate-induced death of primary hippocampal neurons, protect neuronal synapse growth, and reduce hyperoxidation and excitotoxicity (Neurotoxicology, 2021. 85: p. 68-78). In vivo, edaravone can improve cognitive function in various dementia model rats or mice, and reduce markers of intracerebral oxidation, neuroinflammation, Aβ plaque formation, and tau phosphorylation levels. In a scopolamine-induced rat dementia model, oral administration of edaravone at 15 mg / kg / day for 7 consecutive days can improve scopolamine-induced spatial learning and long-term memory impairment (International Journal of Pharmacology, 2013. 9(4): p. 271-276). Aβ oligomerized in the dentate gyrus of the rat hippocampus. 1-40In a model in which Aβ was injected into the brain, intracerebral injection of Aβ and administration of edaravone (5 mg / kg) at the same site significantly improved rats' spatial learning and memory abilities in the water maze, reduced the levels of 4-hydroxy-2-nonenal (4-HNE) adducts in the hippocampus, and restored the AChE and ChAT enzyme activities increased by Aβ injection (Neurological Sciences, 2015. 36(11): p. 2067-2072). In a sporadic AD (SAD) rat model in which learning and memory impairment is induced by injecting STZ (ICV-STZ) into the lateral ventricle, intraperitoneal administration of edaravone at 9 mg / kg / day for 14 consecutive days after the ICV-STZ model was established could significantly improve the spatial learning and memory ability in the Morris water maze test and the non-spatial long-term memory ability in the step-down passive avoidance test in the ICV-STZ model rats, and could significantly restore the changes in various oxidative stress indicators in the hippocampus and cortex caused by the STZ model, including malondialdehyde (MDA), 4-HNE adducts, ·OH, protein carbonyl (PC), H2O2, superoxide dismutase (SOD), reduced glutathione (GSH), and glutathione peroxidase (GPx) (NeuroToxicology, 2013. 38: p. 136-145). In addition, oral administration of edaravone (1, 3 and 10 mg / kg / day) for 28 consecutive days can similarly improve cognitive function in the water maze and passive avoidance tests in ICV-STZ rats and reduce STZ-induced brain oxidative stress, cholinergic abnormalities and inflammation (Eur J Neurosci, 2017. 45(7): p. 987-997). In an AlCl3 / D-galactose chemically induced mouse cognitive impairment model, intraperitoneal administration of edaravone for 15 consecutive days can significantly improve cognitive function in the water maze and step-down tests in mice (Neurotoxicology, 2021. 85: p. 68-78).In addition, in an L-methionine-induced rat vascular dementia model, continuous intraperitoneal administration of edaravone at 6 mg / kg / day for 9 weeks can significantly improve spatial learning and memory ability in the 8-arm water maze test of the model rats (Naunyn Schmiedebergs Arch Pharmacol, 2020. 393(7): p. 1221-1228). In an APP / PS1 transgenic mouse model, both preventive (3-9 months old) and therapeutic (9-12 months old) administration of edaravone at 12.6 mg / kg (intraperitoneal injection, twice a week) can improve cognitive function defects in the water maze test in mice, and reduce the deposition of Aβ plaques in the brain, loss of neurons and neural synapses, as well as neuroinflammation, tau protein phosphorylation (pSer396, pSer262, pSer199 and pThr231), and oxidative stress. Similarly, oral administration (administration in drinking water) of edaravone to mice (3-12 months old) at 33.2 mg / kg / day after conversion based on the bioavailability (38%) in oral administration to mice can also reduce Aβ plaque deposition in the brain and improve cognitive function in mice (Proc Natl Acad Sci USA, 2015. 112(16): p. 5225-30). Furthermore, oral administration of edaravone (8, 24 and 72 mg / kg / day, administered in drinking water) to aged APP / PS mice (14-17 months old) can significantly improve cognitive function in aged transgenic mice (Drug Design, Development and Therapy, 2018. Volume 12: p. 2111-2128). In a tau P301L transgenic mouse model of frontotemporal dementia (FTD), oral administration (administration in drinking water) of edaravone at 24 mg / kg / day for 3 consecutive months to 9-10 month-old and 21 month-old transgenic mice significantly improved the animals' cognitive function in the water maze test and novel object recognition test, improved the animals' motor deficits, and reduced the production of 4-HNE and 3-NT adducts in brain tissue, tau phosphorylation levels, and neuroinflammation (DOI: https: / / doi.org / 10.21203 / rs.3.rs-306628 / v1).
[0008] The chemical structure of edaravone is as follows: [ka]
[0009] Dexborneol ((+)-borneol) is the main component of natural borneol (the 2020 edition of the Chinese Pharmacopoeia stipulates that the dexborneol content in natural borneol is more than 96%). It is a bicyclic monoterpene compound and is present in the volatile oils of many traditional Chinese medicines. Dexborneol can regulate the NF-κB and p38 signal pathways, inhibit inflammatory neuritis, and reduce multiple pro-inflammatory factors (TNF-α, IL-1β, etc.) and inflammatory proteins (iNOS and COX-2) in the brain (Eur J Pharmacol, 2014. 740: p. 522-31, Eur J Pharmacol, 2017. 811: p. 1-11), and further enhance the inhibitory GABA A reception It can stimulate the nervous system and regulate excitatory nerve damage (Front Pharmacol, 2021. 12: p. 606682).
[0010] The chemical structure of dexborneol is as follows: [ka]
[0011] According to non-clinical animal experiments, the composition of 3-methyl-1-phenyl-2-pyrazolin-5-one and dexborneol (mass ratio 4:1 to 1:1) can synergistically reduce cerebral infarction area (issued patent CN101848711B) and improve amyotrophic lateral sclerosis (ALS) (issued patent CN107613976B). In the research and development of new drugs to treat stroke, edaravone dexborneol injectable concentrated solution (a composition having a mass ratio of 3-methyl-1-phenyl-2-pyrazolin-5-one and dexborneol of 4:1) has already been approved by NMPA for treating ischemic stroke in 2020, and Y-2 sublingual tablets (a composition having a mass ratio of 3-methyl-1-phenyl-2-pyrazolin-5-one and dexborneol of 5:1) has already conducted a phase III study in China (China Clinical Registry No. CTR20210233) and a phase I study in the United States (ClinicalTrials.gov NCT03495206).
[0012] According to the prior art, it is impossible to predict whether a composition of 3-methyl-1-phenyl-2-pyrazolin-5-one and dexborneol has a therapeutic effect on dementia and associated cognitive impairment, and it is also impossible to determine whether the conventional composition of 3-methyl-1-phenyl-2-pyrazolin-5-one and dexborneol has a synergistic effect. Summary of the Invention
[0013] The object of the present invention is to provide an application of a pharmaceutical composition in the manufacture of a medicament for improving or treating cognitive dysfunction, the pharmaceutical composition comprising 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone) or a pharma- ceutical acceptable salt thereof and borneol.
[0014] Another object of the present invention is to provide an application of the pharmaceutical composition in improving or treating cognitive dysfunction, wherein a pharmaceutical composition containing 3-methyl-1-phenyl-2-pyrazolin-5-one or a pharma- ceutically acceptable salt thereof and borneol is administered to a patient in need thereof.
[0015] Another object of the present invention is to provide a pharmaceutical composition for treating cognitive dysfunction, wherein said composition comprises 3-methyl-1-phenyl-2-pyrazolin-5-one or a pharma- ceutically acceptable salt thereof and borneol.
[0016] A further object of the present invention is the use of 3-methyl-1-phenyl-2-pyrazolin-5-one or a pharma- ceutically acceptable salt thereof in combination with natural borneol in the treatment of cognitive impairment.
[0017] Furthermore, the combined use of 3-methyl-1-phenyl-2-pyrazolin-5-one or a pharma- ceutically acceptable salt thereof and borneol in the pharmaceutical composition can synergistically increase efficacy in treating cognitive impairment.
[0018] In some embodiments of the present invention, the cognitive impairment is Alzheimer's disease (AD), vascular dementia (VD), mild cognitive impairment (MCI) and other types of dementia, preferably, the cognitive impairment is Alzheimer's disease, vascular dementia and mild cognitive impairment.
[0019] In one embodiment of the present invention, the pharmaceutical composition is capable of improving cognitive function in Alzheimer's disease.
[0020] In another embodiment of the present invention, the pharmaceutical composition can restore long-term potentiation (LTP) in the hippocampal region of Alzheimer's disease and restore the function of hippocampal synapses in the brain.
[0021] In a further embodiment of the invention, the pharmaceutical composition is capable of ameliorating the pathology of Alzheimer's disease including amyloid plaques, astrocyte proliferation, microglial proliferation and hyperphosphorylation of tau protein.
[0022] In the composition according to the present invention, the weight ratio of 3-methyl-1-phenyl-2-pyrazolin-5-one or a pharma- ceutically acceptable salt thereof to borneol is 10:1 to 1:8, preferably 7.5:1 to 2.5:1, and more preferably 5:1 or 4:1.
[0023] The borneol according to the present invention is preferably natural borneol, said natural borneol also being called dexborneol.
[0024] The pharmaceutical compositions according to the present invention may further comprise a pharma- ceutically acceptable excipient.
[0025] Excipients are pharmacologically inactive substances that are typically formulated with the active drug ingredient ("API") of a drug therapy. When producing dosage forms, excipients are often used to bulk up formulations containing the active active ingredient (hence often referred to as "bulking agents," "fillers," or "diluents") to allow for convenient and accurate dispensing of the drug substance. They can also serve different therapeutic enhancement purposes, such as facilitating drug absorption or dissolution, or other pharmacokinetic considerations.
[0026] More specifically, the compositions of the present invention can be prepared as pharmaceutical compositions, alone or in combination with pharma- ceutically acceptable carriers or diluents, and can be prepared as solid, semi-solid, liquid or gaseous formulations, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants, gels, microspheres, aerosols, etc. Thus, administration of the compounds can be accomplished in a variety of forms, including oral, buccal, rectal, parenteral, intraperitoneal, subcutaneous, transdermal, intraductal, intraarticular, etc. The active agent, once administered, can be systemic or localized by topical administration, intramural administration, or the use of an implant that can retain an amount of the active agent at the implantation site.
[0027] The combination therapy used in the present invention allows the dosage of each monotherapy to be lower than those currently used in standard operations, while still achieving significant effects, including effects greater than those achieved when either monotherapy is typically administered. Those skilled in the art will readily appreciate that dosage levels will vary with the specific compound, the severity of symptoms, and the subject's susceptibility to side effects. Some specific compounds are more effective than others. The preferred dosage of a particular compound can be readily ascertained by those skilled in the art by a variety of means. A preferred means is to measure the physiological effects of the particular compound. The use of combination therapy allows the dosage of each monotherapy to be lower than those currently used in standard operations, while still achieving significant effects, including effects greater than those achieved when either monotherapy is typically administered. [Brief description of the drawings]
[0028] [Figure 1] FIG. 1 shows protection of Aβ1-42-induced neuronal damage by edaravondexborneol composition. [Diagram 2] FIG. 2 shows the improvement of spatial learning, memory and cognitive function in ICV-STZ by edaravondex borneol composition. [Diagram 3] FIG. 1 shows the effect of an edaravondexborneol composition on cognitive function in a water maze test in AD transgenic mice. [Figure 4] FIG. 1 shows the effect of an edaravondexborneol composition on cognitive function in a Y-maze test in AD transgenic mice. [Diagram 5] FIG. 1 shows the effect of edaravondexborneol composition on electrophysiology of brain slices from AD transgenic mice. [Figure 6] FIG. 1 shows the effect of edaravondexborneol composition on AD-related pathology in the brain of 5×FAD transgenic mice. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0029] The following examples illustrate the present invention and should not be construed as limiting the present invention. The edaravone referred to in the examples is 3-methyl-1-phenyl-2-pyrazolin-5-one. Example 1: Aβ Inhibition by a Composition of Edaravone and Dexborneol 1-42 Protection against induced primary cortical neuron injury 1. Materials and Methods 1.1 Animals
[0030] SD pregnant rat, Shanghai Silaike Experimental Animals Co., Ltd. (Production license number: SCXK (Hu) 2017-0005) 1.2 Reagents and Consumables
[0031] [Table 1]
[0032] 1.3 Preparation of primary cortical neurons SD pregnant rats at 18 days of gestation were sacrificed by cervical dislocation, and the rat uterus was dissected to extract the E18 fetal brain. The fetal cerebral cortical tissue was isolated in ice-cold DMEM, and the meninges and blood vessels on the cortical tissue were removed under a dissection microscope. The cortical tissue was transferred to ice-cold DMEM and cut (1 mm 3 ), digested with pancreatin at 37°C for 10 min, stopped with FBS, gently blown off with a Pasteur pipette, and passed through a 200 mesh sieve. The filtered cell suspension was transferred to a 15 mL centrifuge tube and centrifuged at 1000 rpm for 5 min. The supernatant was aspirated and discarded, and the cell aggregates at the bottom of the centrifuge tube were gently blown off with complete medium (Neurobasal + B27 + GlutaMax + 1% P / S) preheated at 37°C, counted with a hemocytometer, and counted at 5 × 10 in complete medium. 5 The cells were diluted to 100 cells / mL and inoculated into a 96-well plate coated with PDL (100 μL / well). The next day, half of the medium was replaced with complete medium and the cells were cultured in vitro until neurons differentiated and matured on day 11, and then used for the hypoxia-low glucose tolerance test. 1.4 Aβ 1-42 Inducible excitotoxicity assay for primary cortical neurons
[0033] The medium of in vitro matured primary neurons was replaced with complete medium containing different concentrations (1.2, 3.7, 11.1, 33.3, 100.0 μM) of edaravone (E), dexborneol (B), or edaravone-dexborneol composition (EB). After incubation at 37°C for 30 min, oligomerized Aβ was detected. 1-42 (final concentration 50 μM) was added and the culture was continued for 24 h to detect the viability of neurons. The viability of primary neuronal cells was detected using the Luminescent Cell Viability Assay kit. According to the instruction manual, the reagent was added at 100 μL / well, shaken for 10 min, and the chemiluminescence value (LUM) was read on a SpectraMax i3X (Molecule Device) multifunctional plate reader to calculate the relative viability of neurons. Calculation formula:
number
[0034] [Table 2]
[0035] 1.5 Data Statistics One-way ANOVA (analysis of variance) was performed using Prism software (GraphPad), followed by Uncorrected Fisher's LSD to analyze the differences between the two groups. P<0.05 indicates significant difference. Ex or By were significantly different from the DMSO group, #p<0.05, ####p<0.0001, **p<0.01, ***p<0.001, ****p<0.0001, and ExBy was significantly different from both the Ex and By groups. 2. Experimental Results
[0036] Oligomerized Aβ 1-42 Aβ causes a decrease in the viability of primary neuronal cells. 1-42 Preincubation and administration of edaravone (3.7-100 μM) or dexborneol (1.2-100 μM) before induction can concentration-dependently suppress Aβ-induced neurotoxicity and improve cell viability. The orthogonal compositions of edaravone (1.2, 3.7, 11.1, 33.3, 100.0 μM) and dexborneol (1.2, 3.7, 11.1, 33.3, 100.0 μM) at different concentrations could inhibit Aβ-induced neuronal damage, and in particular, the protective effects of E5B4 (3.3:1), E5B3 (9:1), E4B5 (1:3.3), E4B4 (1:1), E4B3 (3.3:1), E3B5 (1:9), E3B4 (1:3.3), E3B3 (1:1), E3B2 (3.3:1), E3B1 (9:1) and E2B2 (1:1) compositions were significantly superior to the corresponding individual protective effects ( Figure 1 ). From this, it was tentatively determined that a composition in which edaravone and dexborneol have a molar ratio in the range of 9:1 to 1:9 (mass ratio of 10:1 to 1:8) has a synergistic effect. Example 2: Improvement of cognitive function in rats with lateral ventricle STZ injection-induced dementia by a composition of edaravone and dexborneol 1. Experimental materials 1.1 Experimental animals
[0037] Wistar rats, male, weighing 250-300 g, 110 rats, clean grade, provided by Shanghai SCXK Laboratory Animal Co., Ltd., Permit Number: SCXK(Hu)2012-0002. They were kept in the usual manner before and after surgery, with the room temperature kept at 23-25°C, and allowed to eat and drink ad libitum. 1.2 Test Equipment
[0038] Morris water maze (Topscan lite 2.0 analysis software, Clever Systems); Rat Brain Stereotaxic (Cat. no. 51600, Stoeling); Analytical Balance (Cat. no. AL104, Melttler Toledo). 1.3 Test Drug
[0039] Edaravone injection (Zisan®), active ingredient 3-methyl-1-phenyl-2-pyrazolin-5-one. Edaravone dexborneol compositions (weight ratios of 7.5:1, 5:1 and 2.5:1) are prepared and used when necessary, and the solvent control is 8% propylene glycol. 2. Experimental Design 2.1 Experimental Grouping and Dosing
[0040] The experimental animals were divided into five groups, namely, sham operation group, model group, edaravone group (6 mg / kg), edaravone dexborneol (7.5:1) composition (edaravone 6 mg / kg, dexborneol 0.8 mg / kg), edaravone dexborneol (5:1) composition (edaravone 6 mg / kg, dexborneol 1.2 mg / kg), edaravone dexborneol (2.5:1) composition (edaravone 6 mg / kg, dexborneol 2.4 mg / kg). The model and sham operation group animals were administered with the corresponding volume of blank solvent (8% propylene glycol), and all administrations were administered by intraperitoneal injection, with the administration volume being 10 mL / kg. 2.2 Experimental procedure
[0041] In the experiment, except for the sham operation group, the animals that were successfully operated were randomly divided into the model and each treatment group. According to the above dosage setting principle, the animals in each group were intravenously injected with the corresponding drug 4 hours after operation, and then administered once every day for 14 consecutive days, and the Morris water maze experiment was started on the 15th day, and during the water maze detection period, they were administered once every day before the experiment until the entire test was completed. The animals in each group were subjected to the water maze test, including the hidden platform escape latency and the time spent in the original home quadrant after removal. 3. Experimental Method 3.1 Creation of a dementia model by injecting streptozotocin (STZ) into both lateral ventricles in rats
[0042] After anesthetizing the rats, they were stereotaxically fixed in a prone position, a dorsal cervical midline incision was made, the skull was exposed, and the bregma was used as the coordinate, with the position 0.8 mm posterior, 1.5 mm lateral, and 3.6 mm deep from the bregma as the lateral ventricle injection point. Using a microinjector, 10 μL of STZ (prepared with artificial cerebrospinal fluid) was injected into both ventricles, respectively, and the injection was completed within 1 min, with the needle left in for 3 min. After the injection was completed, the skin was sutured. The first day's dose was 1.5 mg / kg, and the STZ injection method of the first day was repeated on the third day, resulting in a total injection amount of 3 mg / kg of STZ. The same volume of artificial cerebrospinal fluid was injected into both lateral ventricles of sham-operated animals. 3.2 Morris water maze experiment
[0043] The Morris water maze pool had a diameter of 160 cm, a height of 50 cm, and a water depth of 29 cm. The platform had a diameter of 12 cm, a height of 27 cm, and was fixed 2 cm below the water surface in the SE quadrant (destination quadrant). The camera lens was placed 2 m above the center of the pool and 2 m from the bottom of the pool to synchronously record the movement trajectory of the rat. The water temperature was maintained at 22 ± 1°C. The experiment lasted for a total of 5 days, including the hidden platform test and the spatial exploration test. The first 4 days were the hidden platform test, and the last day was the spatial exploration experiment.
[0044] (1) Hidden platform trial
[0045] This experiment lasted for 4 days, during testing the platform position was fixed in the target quadrant (SE quadrant) and the animals were placed in the water from the water entry points of each of the four quadrants, during training the animals were placed lightly in the water facing the mark on the wall of the pool, the time it took for the animals to find the platform (escape latency) was recorded, and the animals were allowed to stay on the platform for 10 s. If the platform was not found within 90 s, the latency was recorded as 90 s, and the animals were guided onto the platform and allowed to stay there for 10 s. After the training was completed, the rats were returned to their cages and kept warm. Each day, the rats were trained once at each of the four water entry points, and the average of the four latencies was statistically analyzed as the performance of the day. Each day, the order of the water entry points for each animal was consistent, but the order of water entry for different animals in the same cage was different to eliminate the exchange of information between animals in the group.
[0046] (2) Probe trial
[0047] The platform was removed 24 h after the completion of the hidden platform test. The rats were then placed in water through the water entry point opposite the platform. The swimming path of the rats was recorded within 120 s, and the time spent in the target quadrant was statistically analyzed. The animals' spatial orientation ability and the change in the spatial exploration process were observed. 3.3 Data Statistics
[0048] Data were expressed as Mean ± SEM. Statistical analysis between groups was performed using Prism software (GraphPad, USA), and comparisons between two or more groups were performed using Fisher's LSD test after detection using one-way or two-way ANOVA. P<0.05 indicates significant difference. Compared to the sham-operated group, ####p<0.0001; compared to the model group, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; & p<0.05, && p<0.01 indicate comparisons between the two groups. 4. Experimental Results
[0049] In the water maze hidden platform test, the escape latency was significantly prolonged in the lateral ventricle STZ (ICV-STZ) injection model compared to the sham operation group, indicating cognitive dysfunction in the ICV-STZ rats. Intraperitoneal injection of edaravone (6 mg / kg) or edaravone dexborneol compositions (7.5:1, 5:1 and 2.5:1) can significantly shorten the escape latency of ICV-STZ rats. Compared to the edaravone administration group, the edaravone dexborneol (7.5:1, 5:1 and 2.5:1) compositions were superior to edaravone in improving the learning function of the ICV-STZ model rats ( Figure 2 A). In the water maze spatial exploration test, the ICV-STZ model rats showed a significant reduction in the time spent in the target quadrant. Compared with the model group, the groups administered intraperitoneal injections of edaravone (6 mg / kg) or edaravone-dexborneol composition (7.5:1, 5:1, and 2.5:1) showed a significant increase in the time spent in the target quadrant, and the edaravone-dexborneol composition (5:1 and 2.5:1) groups were significantly superior to the edaravone group ( Figure 2 B). Therefore, the edaravone-dexborneol compositions (7.5:1, 5:1 and 2.5:1) could significantly improve the cognitive function deficits of ICV-STZ rats, and their efficacy was obviously superior to that of edaravone. Example 3: Effect of long-term administration of edaravondex borneol composition on AD cognitive function and AD pathology in 5xFAD transgenic mice 1. Materials and Methods 1.1 Test animals
[0050] Both wild-type WT mice and 5×FAD transgenic mice were provided by the research team of Jian Sima at China Pharmaceutical University. 1.2 Test Drugs and Reagents
[0051] Edaravone, i.e. Edaravone injection (Bissun®, Sunshine Pharmaceuticals), the active ingredient is 3-methyl-1-phenyl-2-pyrazolin-5-one. Edaravone dexborneol composition, i.e. Edaravone dexborneol concentrated solution for injection (Bissun®, Sunshine Pharmaceuticals), the weight ratio of 3-methyl-1-phenyl-2-pyrazolin-5-one to dexborneol is 4:1. The solvent control is 8% propylene glycol. 1.3 Experimental Method
[0052] In this study, mice were divided into four groups, and each group was administered the drug from the age of 8 weeks. After 16 weeks of daily administration, water maze and Y-maze behavioral experiments were performed. After the behavioral detection was completed, the animals were sacrificed and electrophysiological analysis of brain slices and detection of intracerebral AD pathology were performed, including detection of biomarkers such as Aβ plaques, GFAP, and Iba-1, as well as p-Tau. 1.3.1 Animal Grouping and Dosing
[0053] WT: Vehicle control group: 10 wild type mice were administered the vehicle control ip at a dose of 10 mL / kg once daily.
[0054] 5xFAD: Vehicle group: 10 5xFAD mice were administered vehicle control ip at a dose of 10 mL / kg once daily.
[0055] 5xFAD: Edaravone group: 10 5xFAD mice were administered edaravone (Hissin®) 6 mg / kg ip at a dose of 10.0 mL / kg once a day.
[0056] 5xFAD: Composition group: 10 5xFAD mice were administered edaravone dexborneol (Xian Bisin (registered trademark)) 7.5 mg / kg (edaravone:dexborneol=4:1, containing 6 mg / kg edaravone and 1.5 mg / kg dexborneol) i.p. at a dose of 10.0 mL / kg once a day. 1.3.2 Water maze experiment:
[0057] Before the start of the experiment, the mice should be placed in the testing room for approximately 30 min to allow them to acclimate to the environment.
[0058] Experimental preparation: Fresh water was poured into the thermostatic pool of the water maze (inner diameter 120 cm, height 50 cm) and the water temperature was controlled at approximately 18-22°C. The four vertices of the pool were marked as "S", "N", "W", and "E", respectively, and the platform was placed 1-2 cm lower than the water surface in the "SW" direction. Titanium dioxide was added to the water to make it an opaque milky white color.
[0059] Parameter settings: the test duration was set to 1 min, and the mouse's residence time on the platform was set to 2 s.
[0060] Training: The first 5 days were the water maze training phase. Each day, mice were placed in the pool from four different directions, and the trajectory and time before they stepped on the platform, as well as the path and time in each quadrant were recorded. Mice that did not find the platform within 1 min were guided to the platform after 1 min and allowed to stay there for 10-15 s. The specific directions in which the mice were released are shown in Table 1.
[0061] [Table 3]
[0062] Test: The test was conducted on the first day after the training. During the test, the platform was removed, and the test time was 60 s. The mouse was placed in the NE direction, and the number of times the mouse crossed the platform during the test and the time it spent in the platform quadrant were recorded. 1.3.3 Y-maze experiment:
[0063] Before the start of the experiment, the mice should be placed in the testing room for approximately 30 min to allow them to acclimate to the environment.
[0064] Training: One arm of the Y-maze was covered with a shutter, and the mouse was placed at the end of one of the remaining two arms and allowed to explore freely for 15 min, which was then recorded.
[0065] Test: After 1 h of training, the shutter was removed, the aisles of the Y-maze were wiped with alcohol to remove the odor of the previous mouse, and the test mouse was placed in the same position for 5 min and videotaped. During the test, the ratio of the number of times the mouse entered the newly opened arm to the total number of times the mouse entered the three arms was recorded. 1.3.4 Electrophysiological detection in brain slices
[0066] Electrophysiological recordings were performed after the behavioral detection of the mice was completed. All mice were euthanized after anesthesia, and brain tissues were rapidly collected and stored in oxygenated (95% O2 / 5% CO2) artificial cerebrospinal fluid (ACSF) (75 mM sucrose, 87 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 21.4 mM NaHCO3, 0.5 mM CaCl2, 7 mM MgCl2, and 20 mM glucose) at 4 °C. Hippocampal slices were cut in oxygenated ACSF at 4 °C with a vibrating knife and placed in oxygenated ACSF at 32 °C. The slices were then incubated at room temperature for 1 h before recording. Hippocampal LTP was induced by two electrical theta pulse stimulations (TBS). Data collection and analysis were performed using Clampex and Clampfit 8.2 (Molecular Devices). 1.3.5 AD Pathology Detection (Immunohistochemistry Test)
[0067] After the ethological detection was completed, the brains were extracted after cardiac perfusion for the mice, fixed in 4% paraformaldehyde for 24 h, dehydrated in 30% sucrose, flash frozen and embedded in embedding medium, and brain sections (30 μM thick) were performed. Brain sections with hippocampal regions were selected, washed 3 times with PBS for 5 min, permeabilized with 0.2% Triton, washed 3 times with PBS for 7 min, blocked for 1 h with blocking buffer (2.5% BSA, 0.3% Triton), and left in primary antibody at 4 °C overnight. The next day, the brain sections were removed from the primary antibody, washed 3 times with PBS for 5 min, placed in secondary antibody, and incubated at room temperature for 1 h in the dark, and the brain sections were removed, washed 3 times with PBS for 5 min, dropped with DAPI-containing anti-fluorescence quencher, and mounted. 1.4 Statistical analysis
[0068] Data were expressed as Mean ± SEM. Statistical analysis between groups was performed using Prism software (GraphPad, USA), and comparisons between two or more groups were performed using Fisher's LSD test after detection using one-way or two-way ANOVA. P<0.05 indicates significant difference. Compared to the WT group, ##p<0.01, ###p<0.001, and ####p<0.0001; compared to the model group, *p<0.05, **p<0.01, ***p<0.0001, ****p<0.0001; and & p<0.05, &&p<0.01, &&&&p<0.0001 indicate comparisons between the two groups. 2. Experimental Results 2.1 Improvement of cognitive function deficits in AD transgenic mice by Edaravondex borneol composition
[0069] In the Morris water maze test, 24-week-old 5xFAD mice showed cognitive function deficits compared to wild-type mice (WT) of the same age, specifically as follows: in the hidden platform training test, the 5xFAD mice had a significantly longer escape period from 2 to 5 days than the WT mice, and in the platform removal test, the 5xFAD mice had significantly less time in the target quadrant and fewer times of crossing the platform than the WT mice. Compared to the vehicle control, 5xFAD mice were administered 6 mg / kg edaravone or 7.5 mg / kg edaravone-dexborneol composition (containing 6 mg / kg edaravone and 1.5 mg / kg dexborneol) by intraperitoneal injection once a day from the age of 8 weeks for 16 consecutive weeks, significantly shortening the escape latency in the water maze hidden platform test of 5xFAD mice ( Figure 3 A) The residence time in the target quadrant and the number of times the platform is crossed during the platform removal test can be extended ( Figure 3 B, C). Compared with the edaravone-treated group, the composition-treated group showed a shorter escape latency on the fifth day in the hidden platform test, a significantly longer residence time in the target quadrant in the platform removal test, and a higher number of crossings of the platform ( Figure 3 A, B and C). This shows that both edaravone and the edaravone composition can improve the learning, memory and cognitive functions in the water maze test of 5×FAD mice, and the improving effect of the composition is significantly superior to that of edaravone.
[0070] In the Y-maze, 24-week-old 5×FAD mice showed cognitive function defects compared to wild-type mice (WT) of the same age, specifically as follows: 5×FAD mice had a significantly decreased rate of entry into new arms, i.e., decreased spatial reference memory function. Compared with the solvent control, 6 mg / kg edaravone or 7.5 mg / kg edaravone dexborneol composition (containing 6 mg / kg edaravone and 1.5 mg / kg dexborneol) was administered to 5×FAD mice from the age of 8 weeks by intraperitoneal injection once a day for 16 consecutive weeks, which can significantly increase the rate of entry into new arms of 5×FAD mice. Compared with edaravone, the edaravone dexborneol composition was significantly more effective in increasing the rate of entry into new arms of 5×FAD mice ( Figure 4 ) This shows that both edaravone and the edaravone composition can improve the spatial reference memory cognitive function in the Y-maze test of 5×FAD mice, and the improving effect of the composition is significantly superior to that of edaravone. 2.2 Recovery of synaptic transmission function in the hippocampus of AD mice by Edaravondex-borneol composition
[0071] Long-term potentiation (LTP) reflects the plasticity of synaptic function and is one of the main mechanisms of learning and memory. After the water maze and Y-maze tests were completed, electrophysiological detection showed that the hippocampal LTP of the 5×FAD mice was significantly impaired. Compared with the 5×FAD mice group, the administration of the composition can significantly restore the mouse hippocampal LTP, but the administration of edaravone had no obvious restorative effect on the hippocampal LTP of the 5×FAD mice, and the LTP recovery in the case of the composition administration was also significantly better than that of the edaravone group ( Figure 5 A, B and C). This shows that the plasticity of hippocampal synapses in 24-week-old 5×FAD transgenic mice is impaired, while Edaravondexborneol composition can promote hippocampal neuroplasticity and restore hippocampal LTP to a better level. 2.3 Edaravondex-borneol composition improves AD pathology in the brain of AD mice
[0072] Obvious AD pathology was observed in the brains of 24-week-old 5×FAD mice, including β-amyloid plaques, astrocyte proliferation, microglia proliferation, and hyperphosphorylation of tau protein in neurons in the hippocampus. Compared with the solvent control group, 6 mg / kg edaravone or 7.5 mg / kg edaravone dexborneol composition (containing 6 mg / kg edaravone and 1.5 mg / kg dexborneol) was administered to 5×FAD mice from 8 weeks of age by intraperitoneal injection once a day for 16 consecutive weeks, which can significantly reduce AD pathology (β-amyloid plaques, astrocyte proliferation, microglia proliferation) in the brain and tau phosphorylation levels in the hippocampus. Compared with the edaravone-administered group, the edaravone dexborneol composition has a significant advantage in efficacy in improving AD pathology (β-amyloid plaques, astrocyte proliferation, microglia proliferation) and reducing tau phosphorylation levels ( Figure 6 ).
Claims
1. 2. The use of a composition in improving or treating a cognitive disorder, the composition comprising 3-methyl-1-phenyl-2-pyrazolin-5-one or a pharma- ceutically acceptable salt thereof and borneol or dexborneol.
2. The application of claim 1, characterized in that the composition comprises 3-methyl-1-phenyl-2-pyrazolin-5-one or a pharma- ceutically acceptable salt thereof and dexborneol.
3. The application according to claim 1, characterized in that the weight ratio of the 3-methyl-1-phenyl-2-pyrazolin-5-one or its pharma- ceutically acceptable salt to borneol or dexborneol is 10:1 to 1:
8.
4. The application according to claim 1, characterized in that the weight ratio of the 3-methyl-1-phenyl-2-pyrazolin-5-one or its pharma- ceutically acceptable salt to borneol or dexborneol is 7.5:1 to 2.5:
1.
5. The application according to claim 1, characterized in that the weight ratio of the 3-methyl-1-phenyl-2-pyrazolin-5-one or its pharma- ceutically acceptable salt to borneol or dexborneol is 5:
1.
6. The application according to claim 1, characterized in that the weight ratio of the 3-methyl-1-phenyl-2-pyrazolin-5-one or its pharma- ceutically acceptable salt to borneol or dexborneol is 4:
1.
7. The application according to claims 1 to 6, characterized in that the composition further comprises a pharma- ceutically acceptable excipient.
8. The application according to claims 1 to 6, characterized in that the cognitive impairment refers to Alzheimer's disease, vascular dementia, mild cognitive impairment and other types of dementia.
9. The application according to claims 1 to 6, characterized in that the cognitive disorders refer to Alzheimer's disease, vascular dementia and mild cognitive impairment.
10. The application according to claims 1 to 6, characterized in that the cognitive disorder refers to Alzheimer's disease.
Citation Information
Patent Citations
Application of the composition in the preparation of amyotrophic lateral sclerosis therapeutic drug
JP2018515621A
